Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020
November 12, 2020 at 02:37 pm EST
Share
Genovate Biotechnology Co., Ltd. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced sales was TWD 121.399 million compared to TWD 110.108 million a year ago. Operating income was TWD 13.342 million compared to TWD 3.378 million a year ago. Net income was TWD 14.322 million compared to TWD 3.900 million a year ago. Basic earnings per share was TWD 0.14 compared to TWD 0.04 a year ago. For the nine months, sales was TWD 381.267 million compared to TWD 359.760 million a year ago. Operating income was TWD 47.810 million compared to TWD 41.431 million a year ago. Net income was TWD 46.990 million compared to TWD 38.515 million a year ago. Basic earnings per share was TWD 0.44 compared to TWD 0.36 a year ago.
Genovate Biotechnology Co., LTD. is a Taiwan-based company principally engaged in the research, development, manufacture and sales of pharmaceutical preparations, drug substances and intermediates. The Company's products include nervous system drugs, digestive system drugs, analgesic and anti-inflammatory drugs, urogenital system drugs, antimicrobial drugs, cardiovascular system drugs, acne drugs, antineoplastic drugs and anti-diabetic drugs, as well as healthcare food and cosmetics. The Company is also engaged in the provision of clinical experimental testing services and technology export services. The Company distributes its products mainly within domestic market.
GENOVATE BIOTECHNOLOGY CO., LTD. 